Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EUPAS10335 | Registry Identifier | EU PAS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes.
The study enroll a large population of approximately 252467 participants. The study would analyze association of cancer and pioglitazone in 2 cohorts based on the usage of pioglitazone. Participants in were originally planned to be followed-up from January 1, 1997 to December 31, 2005. Based on the discussion with advisory board, it was recommended to increase the study population and duration of follow-up. The follow-up period was extended to June 30, 2012 for the study.
This multi-center trial was conducted in the United States of America. The overall time to participate in this study was approximately 15.5 years. Participants were followed-up from January 1, 1997 up to June 30, 2012 for the assessment of cancer risk associated with pioglitazone use.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ever User of Pioglitazone | Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period. |
| |
| Never User of Pioglitazone | Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pioglitazone | Drug | Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1. |
| Measure | Description | Time Frame |
|---|---|---|
| Hazard Ratio of the 10 Most Common Cancers Associated With Ever Use of Pioglitazone | The hazard ratio of the 10 most common cancers: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with ever use of pioglitazone. Cox proportional hazards regression modeling was used to provide point and interval estimates of the relative hazard of the 10 most common cancers associated with ever use of pioglitazone. In all regression analyses, these measures of exposure to pioglitazone were treated as time-dependent covariates and time since entry into the cohort was the time scale. | 15 years 5 months |
| Number of 10 Most Common Cancers Associated Cases | Number of 10 most common cancer cases are reported in this measure: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma. | 15 years 5 months |
| Measure | Description | Time Frame |
|---|---|---|
| Hazard Ratio of the 10 Most Common Cancers Associated With Time Since First Use of Pioglitazone | The hazard ratio of the 10 most common cancers: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with time since first use of pioglitazone. The various times since initiation include <12 months ago, 12-23 months ago, 24-35 months ago, 36-47 months ago, 48-83 months ago and 84+ months ago. Cox proportional hazards regression modeling was used to provide point and interval estimates of the time since first use. In all regression analyses, these measures of exposure to pioglitazone were treated as time-dependent covariates and time since entry into the cohort was the time scale. |
Not provided
Inclusion Criteria:
Exclusion Criteria: 1. Age less than (<) 40 years during study period. 2. No KPNC medication benefits at the time of entry into the cohort (baseline) or gap in medication benefit greater than equal to (>=) 4 months that started in the first 4 months after entering in the cohort.
3. Gap in KPNC membership >= 4 months that started in the first 4 months after entering in the cohort.
4. Participant with a diagnosis of Human immunodeficiency virus (HIV). 5. Participants with evidence of selected surgeries for some cancer sites. 6. All prevalent cancers at baseline, that is, all participants ever diagnosed with cancer other than non-melanoma skin cancer.
Not provided
Not provided
Not provided
Participants with a historical diagnosis of Type 2 diabetes mellitus (T2DM) with pioglitazone exposure identified from the Kaiser Permanente of Northern California(KPNC) Diabetes Registry (with or without diabetes) and had completed Member Health Survey (MHS) were enrolled in the epidemiology study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Takeda | Study Director |
Not provided
Participants with a historical diagnosis of T2DM with pioglitazone exposure identified from the Kaiser Permanente of Northern California(KPNC) Diabetes Registry were enrolled in this observational study.
Participants took part in the study at 2 investigative sites in the United States from 01 July 1997 to 30 June 2012.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ever User of Pioglitazone | Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period. |
| FG001 | Never User of Pioglitazone | Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Population consisted of Type 2 diabetes mellitus (T2DM) participants who were identified from the Kaiser Diabetes Registry, were included in the membership database, medication benefit database, hospitalization and surgery procedures databases, cancer registry database merged along with data in the diabetes registry were evaluable for analysis.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ever User of Pioglitazone | Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period. |
| BG001 | Never User of Pioglitazone | Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Hazard Ratio of the 10 Most Common Cancers Associated With Ever Use of Pioglitazone | The hazard ratio of the 10 most common cancers: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with ever use of pioglitazone. Cox proportional hazards regression modeling was used to provide point and interval estimates of the relative hazard of the 10 most common cancers associated with ever use of pioglitazone. In all regression analyses, these measures of exposure to pioglitazone were treated as time-dependent covariates and time since entry into the cohort was the time scale. | Analysis population included T2DM participants who were identified from the KPNC Diabetes Registry in the study 1. | Posted | Number | 95% Confidence Interval | Ratio | 15 years 5 months |
|
Not provided
Due to the observational nature of study individual adverse events (AEs) were not planned to be collected and reported.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ever User of Pioglitazone | Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Director | Takeda | +1-877-825-3327 | clinicaltrialregistry@tpna.com |
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077205 | Pioglitazone |
| ID | Term |
|---|---|
| D045162 | Thiazolidinediones |
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
| 15 years 5 months |
| Number of 10 Most Common Cancers Cases by Time Since First Use of Pioglitazone | Number of 10 most common cancer cases: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with time since first use of pioglitazone. Time since initiation of pioglitazone was categorized as <12 months ago, 12-23 months ago, 24-35 months ago, 36-47 months ago, 48-83 months ago and 84+ months ago. | 15 years 5 months |
| Hazard Ratio of the 10 Most Common Cancers Associated With Duration of Pioglitazone | The hazard ratio of the 10 most common cancers: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with duration of pioglitazone. The duration of pioglitazone was categorized as <12 months, 12-23 months, 24-35 months, 36-59 months, 60+ months. Cox proportional hazards regression modeling was used to provide point and interval estimates of the cumulative duration. In all regression analyses, these measures of exposure to pioglitazone were treated as time-dependent covariates and time since entry into the cohort was the time scale. | 15 years 5 months |
| Number of 10 Most Common Cancer Cases by Duration of Pioglitazone | The 10 most common cancer cases included: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with duration of pioglitazone. The duration of pioglitazone was categorized as <12 months, 12-23 months, 24-35 months, 36-59 months, 60+ months. | 15 years 5 months |
| Hazard Ratio of the 10 Most Common Cancers Associated With Cumulative Dose of Pioglitazone | The hazard ratio of the 10 most common cancers: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with dose of pioglitazone. The various doses include 1-9000 mg, 9001-25000 mg, 25001-50000 milligram (mg) and greater than or equal to (>=) 50001 mg. Cox proportional hazards regression modeling was used to provide point and interval estimates of the dose. In all regression analyses, these measures of exposure to pioglitazone were treated as time-dependent covariates and time since entry into the cohort was the time scale. | 15 years 5 months |
| Number of 10 Most Common Cancer Cases By Dose of Pioglitazone | The 10 most common cancer cases included: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with dose of pioglitazone. The various doses include 1-9000 mg, 9001-25000 mg, 25001-50000 mg and >=50001 mg. | 15 years 5 months |
| BG002 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Number | Participants |
|
| Smoking | Number | Participants |
|
| Income | Income was categorized as high and low based on whether the annual household income lied above or below the average census block median income for the cohort (59,000 US Dollars). | Number | Participants |
|
| Renal function | Renal function was measured based on the levels of creatinine: normal creatinine (less than [<] 1.5 milligram per deciliter [mg/dL] for males and <1.4 mg/dL for females) and elevated creatinine (greater than or equal to [>=] 1.5 mg/dL for males and >=1.4 mg/dL for females). | Number | Participants |
|
| Congestive Heart Failure | Number | Participants |
|
| Baseline Glycosylated Hemoglobin (HbA1c) | Number | Participants |
|
| Time since diabetes diagnosis | Number | Participants |
|
|
|
| Primary | Number of 10 Most Common Cancers Associated Cases | Number of 10 most common cancer cases are reported in this measure: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma. | Analysis population included T2DM participants who were identified from the KPNC Diabetes Registry in the study 1. | Posted | Number | Cases | 15 years 5 months |
|
|
|
| Secondary | Hazard Ratio of the 10 Most Common Cancers Associated With Time Since First Use of Pioglitazone | The hazard ratio of the 10 most common cancers: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with time since first use of pioglitazone. The various times since initiation include <12 months ago, 12-23 months ago, 24-35 months ago, 36-47 months ago, 48-83 months ago and 84+ months ago. Cox proportional hazards regression modeling was used to provide point and interval estimates of the time since first use. In all regression analyses, these measures of exposure to pioglitazone were treated as time-dependent covariates and time since entry into the cohort was the time scale. | Analysis population included T2DM participants who were identified from the KPNC Diabetes Registry in the study 1. | Posted | Number | 95% Confidence Interval | Ratio | 15 years 5 months |
|
|
|
| Secondary | Number of 10 Most Common Cancers Cases by Time Since First Use of Pioglitazone | Number of 10 most common cancer cases: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with time since first use of pioglitazone. Time since initiation of pioglitazone was categorized as <12 months ago, 12-23 months ago, 24-35 months ago, 36-47 months ago, 48-83 months ago and 84+ months ago. | Analysis population included T2DM participants who were identified from the KPNC Diabetes Registry in the study 1. The unexposed arm was not planned to be analyzed for this outcome measure. | Posted | Number | Cases | 15 years 5 months |
|
|
|
| Secondary | Hazard Ratio of the 10 Most Common Cancers Associated With Duration of Pioglitazone | The hazard ratio of the 10 most common cancers: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with duration of pioglitazone. The duration of pioglitazone was categorized as <12 months, 12-23 months, 24-35 months, 36-59 months, 60+ months. Cox proportional hazards regression modeling was used to provide point and interval estimates of the cumulative duration. In all regression analyses, these measures of exposure to pioglitazone were treated as time-dependent covariates and time since entry into the cohort was the time scale. | Analysis population included T2DM participants who were identified from the KPNC Diabetes Registry in the study 1. | Posted | Number | 95% Confidence Interval | Ratio | 15 years 5 months |
|
|
|
| Secondary | Number of 10 Most Common Cancer Cases by Duration of Pioglitazone | The 10 most common cancer cases included: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with duration of pioglitazone. The duration of pioglitazone was categorized as <12 months, 12-23 months, 24-35 months, 36-59 months, 60+ months. | Analysis population included T2DM participants who were identified from the KPNC Diabetes Registry in the study 1. The unexposed arm was not planned to be analyzed for this outcome measure. | Posted | Number | Cases | 15 years 5 months |
|
|
|
| Secondary | Hazard Ratio of the 10 Most Common Cancers Associated With Cumulative Dose of Pioglitazone | The hazard ratio of the 10 most common cancers: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with dose of pioglitazone. The various doses include 1-9000 mg, 9001-25000 mg, 25001-50000 milligram (mg) and greater than or equal to (>=) 50001 mg. Cox proportional hazards regression modeling was used to provide point and interval estimates of the dose. In all regression analyses, these measures of exposure to pioglitazone were treated as time-dependent covariates and time since entry into the cohort was the time scale. | Analysis population included T2DM participants who were identified from the KPNC Diabetes Registry in the study 1. | Posted | Number | 95% Confidence Interval | Ratio | 15 years 5 months |
|
|
|
| Secondary | Number of 10 Most Common Cancer Cases By Dose of Pioglitazone | The 10 most common cancer cases included: prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma associated with dose of pioglitazone. The various doses include 1-9000 mg, 9001-25000 mg, 25001-50000 mg and >=50001 mg. | Analysis population included T2DM participants who were identified from the KPNC Diabetes Registry in the study 1.The unexposed arm was not planned to be analyzed for this outcome measure. | Posted | Number | Cases | 15 years 5 months |
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | Never User of Pioglitazone | Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone. | 0 | 0 | 0 | 0 |
No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.
| D001393 |
| Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| Lung/Bronchus |
|
| Colon |
|
| Non-Hodgkin Lymphoma |
|
| Corpus Uteri |
|
| Pancreatic |
|
| Kidney/Renal Pelvis |
|
| Rectum |
|
| Melanoma |
|
|
| Prostate: 36-47 months ago |
|
| Prostate: 48-83 months ago |
|
| Prostate: 84+ months ago |
|
| Breast: <12 months ago |
|
| Breast: 12-23 months ago |
|
| Breast: 24-35 months ago |
|
| Breast: 36-47 months ago |
|
| Breast: 48-83 months ago |
|
| Breast: 84+ months ago |
|
| Lung/Bronchus: <12 months ago |
|
| Lung/Bronchus: 12-23 months ago |
|
| Lung/Bronchus: 24-35 months ago |
|
| Lung/Bronchus: 36-47 months ago |
|
| Lung/Bronchus: 48-83 months ago |
|
| Lung/Bronchus: 84+ months ago |
|
| Colon: <12 months ago |
|
| Colon: 12-23 months ago |
|
| Colon: 24-35 months ago |
|
| Colon: 36-47 months ago |
|
| Colon: 48-83 months ago |
|
| Colon: 84+ months ago |
|
| Non-Hodgkin Lymphoma: <12 months ago |
|
| Non-Hodgkin Lymphoma: 12-23 months ago |
|
| Non-Hodgkin Lymphoma: 24-35 months ago |
|
| Non-Hodgkin Lymphoma: 36-47 months ago |
|
| Non-Hodgkin Lymphoma: 48-83 months ago |
|
| Non-Hodgkin Lymphoma: 84+ months ago |
|
| Corpus Uteri: <12 months ago |
|
| Corpus Uteri: 12-23 months ago |
|
| Corpus Uteri: 24-35 months ago |
|
| Corpus Uteri: 36-47 months ago |
|
| Corpus Uteri: 48-83 months ago |
|
| Corpus Uteri: 84+ months ago |
|
| Pancreatic: <12 months ago |
|
| Pancreatic: 12-23 months ago |
|
| Pancreatic: 24-35 months ago |
|
| Pancreatic: 36-47 months ago |
|
| Pancreatic: 48-83 months ago |
|
| Pancreatic: 84+ months ago |
|
| Kidney/Renal Pelvis: <12 months ago |
|
| Kidney/Renal Pelvis: 12-23 months ago |
|
| Kidney/Renal Pelvis: 24-35 months ago |
|
| Kidney/Renal Pelvis: 36-47 months ago |
|
| Kidney/Renal Pelvis: 48-83 months ago |
|
| Kidney/Renal Pelvis: 84+ months ago |
|
| Rectum: <12 months ago |
|
| Rectum: 12-23 months ago |
|
| Rectum: 24-35 months ago |
|
| Rectum: 36-47 months ago |
|
| Rectum: 48-83 months ago |
|
| Rectum: 84+ months ago |
|
| Melanoma: <12 months ago |
|
| Melanoma: 12-23 months ago |
|
| Melanoma: 24-35 months ago |
|
| Melanoma: 36-47 months ago |
|
| Melanoma: 48-83 months ago |
|
| Melanoma: 84+ months ago |
|
| Title | Measurements |
|---|---|
|
| Prostate: 36-47 months ago |
|
| Prostate: 48-83 months ago |
|
| Prostate: 84+ months ago |
|
| Breast: <12 months ago |
|
| Breast: 12-23 months ago |
|
| Breast: 24-35 months ago |
|
| Breast: 36-47 months ago |
|
| Breast: 48-83 months ago |
|
| Breast: 84+ months ago |
|
| Lung/Bronchus: <12 months ago |
|
| Lung/Bronchus: 12-23 months ago |
|
| Lung/Bronchus: 24-35 months ago |
|
| Lung/Bronchus: 36-47 months ago |
|
| Lung/Bronchus: 48-83 months ago |
|
| Lung/Bronchus: 84+ months ago |
|
| Colon: <12 months ago |
|
| Colon: 12-23 months ago |
|
| Colon: 24-35 months ago |
|
| Colon: 36-47 months ago |
|
| Colon: 48-83 months ago |
|
| Colon: 84+ months ago |
|
| Non-Hodgkin Lymphoma: <12 months ago |
|
| Non-Hodgkin Lymphoma: 12-23 months ago |
|
| Non-Hodgkin Lymphoma: 24-35 months ago |
|
| Non-Hodgkin Lymphoma: 36-47 months ago |
|
| Non-Hodgkin Lymphoma: 48-83 months ago |
|
| Non-Hodgkin Lymphoma: 84+ months ago |
|
| Corpus Uteri: <12 months ago |
|
| Corpus Uteri: 12-23 months ago |
|
| Corpus Uteri: 24-35 months ago |
|
| Corpus Uteri: 36-47 months ago |
|
| Corpus Uteri: 48-83 months ago |
|
| Corpus Uteri: 84+ months ago |
|
| Pancreatic: <12 months ago |
|
| Pancreatic: 12-23 months ago |
|
| Pancreatic: 24-35 months ago |
|
| Pancreatic: 36-47 months ago |
|
| Pancreatic: 48-83 months ago |
|
| Pancreatic: 84+ months ago |
|
| Kidney/Renal Pelvis: <12 months ago |
|
| Kidney/Renal Pelvis: 12-23 months ago |
|
| Kidney/Renal Pelvis: 24-35 months ago |
|
| Kidney/Renal Pelvis: 36-47 months ago |
|
| Kidney/Renal Pelvis: 48-83 months ago |
|
| Kidney/Renal Pelvis: 84+ months ago |
|
| Rectum: <12 months ago |
|
| Rectum: 12-23 months ago |
|
| Rectum: 24-35 months ago |
|
| Rectum: 36-47 months ago |
|
| Rectum: 48-83 months ago |
|
| Rectum: 84+ months ago |
|
| Melanoma: <12 months ago |
|
| Melanoma: 12-23 months ago |
|
| Melanoma: 24-35 months ago |
|
| Melanoma: 36-47 months ago |
|
| Melanoma: 48-83 months ago |
|
| Melanoma: 84+ months ago |
|
| Title | Measurements |
|---|---|
|
| Prostate: 36-59 months |
|
| Prostate: 60+ months |
|
| Breast: <12 months |
|
| Breast: 12-23 months |
|
| Breast: 24-35 months |
|
| Breast: 36-59 months |
|
| Breast: 60+ months |
|
| Lung/Bronchus: <12 months |
|
| Lung/Bronchus: 12-23 months |
|
| Lung/Bronchus: 24-35 months |
|
| Lung/Bronchus: 36-59 months |
|
| Lung/Bronchus: 60+ months |
|
| Colon: <12 months |
|
| Colon: 12-23 months |
|
| Colon: 24-35 months |
|
| Colon: 36-59 months |
|
| Colon: 60+ months |
|
| Non-Hodgkin Lymphoma: <12 months |
|
| Non-Hodgkin Lymphoma: 12-23 months |
|
| Non-Hodgkin Lymphoma: 24-35 months |
|
| Non-Hodgkin Lymphoma: 36-59 months |
|
| Non-Hodgkin Lymphoma: 60+ months |
|
| Corpus Uteri: <12 months |
|
| Corpus Uteri: 12-23 months |
|
| Corpus Uteri: 24-35 months |
|
| Corpus Uteri: 36-59 months |
|
| Corpus Uteri: 60+ months |
|
| Pancreatic: <12 months |
|
| Pancreatic: 12-23 months |
|
| Pancreatic: 24-35 months |
|
| Pancreatic: 36-59 months |
|
| Pancreatic: 60+ months |
|
| Kidney/Renal Pelvis: <12 months |
|
| Kidney/Renal Pelvis: 12-23 months |
|
| Kidney/Renal Pelvis: 24-35 months |
|
| Kidney/Renal Pelvis: 36-59 months |
|
| Kidney/Renal Pelvis: 60+ months |
|
| Rectum: <12 months |
|
| Rectum: 12-23 months |
|
| Rectum: 24-35 months |
|
| Rectum: 36-59 months |
|
| Rectum: 60+ months |
|
| Melanoma: <12 months |
|
| Melanoma: 12-23 months |
|
| Melanoma: 24-35 months |
|
| Melanoma: 36-59 months |
|
| Melanoma: 60+ months |
|
| Title | Measurements |
|---|---|
|
| Prostate: 36-59 months |
|
| Prostate: 60+ months |
|
| Breast: <12 months |
|
| Breast: 12-23 months |
|
| Breast: 24-35 months |
|
| Breast: 36-59 months |
|
| Breast: 60+ months |
|
| Lung/Bronchus: <12 months |
|
| Lung/Bronchus: 12-23 months |
|
| Lung/Bronchus: 24-35 months |
|
| Lung/Bronchus: 36-59 months |
|
| Lung/Bronchus: 60+ months |
|
| Colon: <12 months |
|
| Colon: 12-23 months |
|
| Colon: 24-35 months |
|
| Colon: 36-59 months |
|
| Colon: 60+ months |
|
| Non-Hodgkin Lymphoma: <12 months |
|
| Non-Hodgkin Lymphoma: 12-23 months |
|
| Non-Hodgkin Lymphoma: 24-35 months |
|
| Non-Hodgkin Lymphoma: 36-59 months |
|
| Non-Hodgkin Lymphoma: 60+ months |
|
| Corpus Uteri: <12 months |
|
| Corpus Uteri: 12-23 months |
|
| Corpus Uteri: 24-35 months |
|
| Corpus Uteri: 36-59 months |
|
| Corpus Uteri: 60+ months |
|
| Pancreatic: <12 months |
|
| Pancreatic: 12-23 months |
|
| Pancreatic: 24-35 months |
|
| Pancreatic: 36-59 months |
|
| Pancreatic: 60+ months |
|
| Kidney/Renal Pelvis: <12 months |
|
| Kidney/Renal Pelvis: 12-23 months |
|
| Kidney/Renal Pelvis: 24-35 months |
|
| Kidney/Renal Pelvis: 36-59 months |
|
| Kidney/Renal Pelvis: 60+ months |
|
| Rectum: <12 months |
|
| Rectum: 12-23 months |
|
| Rectum: 24-35 months |
|
| Rectum: 36-59 months |
|
| Rectum: 60+ months |
|
| Melanoma: <12 months |
|
| Melanoma: 12-23 months |
|
| Melanoma: 24-35 months |
|
| Melanoma: 36-59 months |
|
| Melanoma: 60+ months |
|
|
| Prostate: >=50001 mg |
|
| Breast: 1-9000 mg |
|
| Breast: 9001-25000 mg |
|
| Breast: 25001-50000 mg |
|
| Breast: >=50001 mg |
|
| Lung/Bronchus: 1-9000 mg |
|
| Lung/Bronchus: 9001-25000 mg |
|
| Lung/Bronchus: 25001-50000 mg |
|
| Lung/Bronchus: >=50001 mg |
|
| Colon: 1-9000 mg |
|
| Colon: 9001-25000 mg |
|
| Colon: 25001-50000 mg |
|
| Colon: >=50001 mg |
|
| Non-Hodgkin Lymphoma: 1-9000 mg |
|
| Non-Hodgkin Lymphoma: 9001-25000 mg |
|
| Non-Hodgkin Lymphoma: 25001-50000 mg |
|
| Non-Hodgkin Lymphoma: >=50001 mg |
|
| Corpus Uteri: 1-9000 mg |
|
| Corpus Uteri: 9001-25000 mg |
|
| Corpus Uteri: 25001-50000 mg |
|
| Corpus Uteri: >=50001 mg |
|
| Pancreatic: 1-9000 mg |
|
| Pancreatic: 9001-25000 mg |
|
| Pancreatic: 25001-50000 mg |
|
| Pancreatic: >=50001 mg |
|
| Kidney/Renal Pelvis: 1-9000 mg |
|
| Kidney/Renal Pelvis: 9001-25000 mg |
|
| Kidney/Renal Pelvis: 25001-50000 mg |
|
| Kidney/Renal Pelvis: >=50001 mg |
|
| Rectum: 1-9000 mg |
|
| Rectum: 9001-25000 mg |
|
| Rectum: 25001-50000 mg |
|
| Rectum: >=50001 mg |
|
| Melanoma: 1-9000 mg |
|
| Melanoma: 9001-25000 mg |
|
| Melanoma: 25001-50000 mg |
|
| Melanoma: >=50001 mg |
|
| Title | Measurements |
|---|---|
|
| Prostate: >=50001 mg |
|
| Breast: 1-9000 mg |
|
| Breast: 9001-25000 mg |
|
| Breast: 25001-50000 mg |
|
| Breast: >=50001 mg |
|
| Lung/Bronchus: 1-9000 mg |
|
| Lung/Bronchus: 9001-25000 mg |
|
| Lung/Bronchus: 25001-50000 mg |
|
| Lung/Bronchus: >=50001 mg |
|
| Colon: 1-9000 mg |
|
| Colon: 9001-25000 mg |
|
| Colon: 25001-50000 mg |
|
| Colon: >=50001 mg |
|
| Non-Hodgkin Lymphoma: 1-9000 mg |
|
| Non-Hodgkin Lymphoma: 9001-25000 mg |
|
| Non-Hodgkin Lymphoma: 25001-50000 mg |
|
| Non-Hodgkin Lymphoma: >=50001 mg |
|
| Corpus Uteri: 1-9000 mg |
|
| Corpus Uteri: 9001-25000 mg |
|
| Corpus Uteri: 25001-50000 mg |
|
| Corpus Uteri: >=50001 mg |
|
| Pancreatic: 1-9000 mg |
|
| Pancreatic: 9001-25000 mg |
|
| Pancreatic: 25001-50000 mg |
|
| Pancreatic: >=50001 mg |
|
| Kidney/Renal Pelvis: 1-9000 mg |
|
| Kidney/Renal Pelvis: 9001-25000 mg |
|
| Kidney/Renal Pelvis: 25001-50000 mg |
|
| Kidney/Renal Pelvis: >=50001 mg |
|
| Rectum: 1-9000 mg |
|
| Rectum: 9001-25000 mg |
|
| Rectum: 25001-50000 mg |
|
| Rectum: >=50001 mg |
|
| Melanoma: 1-9000 mg |
|
| Melanoma: 9001-25000 mg |
|
| Melanoma: 25001-50000 mg |
|
| Melanoma: >=50001 mg |
|